The Chemours Company (NYSE:CC) Given Consensus Rating of "Moderate Buy" by Brokerages

The Chemours Company (NYSE:CC - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine research firms that are covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $17.22.

Several analysts have recently weighed in on CC shares. Royal Bank Of Canada dropped their price target on shares of Chemours from $17.00 to $14.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. Wall Street Zen cut shares of Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. The Goldman Sachs Group dropped their price target on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a research note on Wednesday, May 14th. Truist Financial dropped their price target on shares of Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Finally, UBS Group lowered their price objective on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th.

Chemours Stock Down 2.3%

Shares of NYSE CC opened at $10.75 on Friday. Chemours has a 12-month low of $9.13 and a 12-month high of $25.54. The stock has a market cap of $1.61 billion, a PE ratio of 53.75 and a beta of 1.64. The company has a current ratio of 1.75, a quick ratio of 0.83 and a debt-to-equity ratio of 7.01. The company has a 50-day moving average of $11.22 and a 200 day moving average of $14.62.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The specialty chemicals company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.06). Chemours had a net margin of 0.54% and a return on equity of 23.82%. The business had revenue of $1.37 billion for the quarter, compared to analysts' expectations of $1.36 billion. During the same period in the prior year, the company posted $0.32 EPS. The firm's revenue was up .4% on a year-over-year basis. As a group, sell-side analysts predict that Chemours will post 2.03 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently announced a dividend, which was paid on Monday, June 16th. Shareholders of record on Monday, May 19th were issued a dividend of $0.0875 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a yield of 3.17%. Chemours's dividend payout ratio (DPR) is presently 175.00%.

Insiders Place Their Bets

In other Chemours news, insider Damian Gumpel bought 13,400 shares of Chemours stock in a transaction on Monday, June 2nd. The shares were bought at an average cost of $9.22 per share, for a total transaction of $123,548.00. Following the acquisition, the insider now directly owns 123,879 shares in the company, valued at $1,142,164.38. This represents a 12.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Shane Hostetter bought 4,450 shares of Chemours stock in a transaction on Monday, May 19th. The shares were acquired at an average price of $11.28 per share, for a total transaction of $50,196.00. Following the completion of the acquisition, the chief financial officer now owns 59,694 shares in the company, valued at $673,348.32. This represents a 8.06% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 25,672 shares of company stock worth $251,573 in the last ninety days. 0.47% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Chemours

Hedge funds and other institutional investors have recently modified their holdings of the company. FNY Investment Advisers LLC purchased a new position in shares of Chemours in the 1st quarter valued at $27,000. UMB Bank n.a. grew its position in shares of Chemours by 73.9% in the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after buying an additional 948 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after buying an additional 1,444 shares during the last quarter. SouthState Corp purchased a new position in shares of Chemours in the 1st quarter valued at $34,000. Finally, Quadrant Capital Group LLC grew its position in shares of Chemours by 100.4% in the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock valued at $38,000 after buying an additional 1,119 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.